Placeholder
Placeholder
    US Content
    Back to Products

    Direct Load Tube Collection Kit

    No uncapping.
    No specimen transfer.

    Find Support
    Placeholder image

      Overview

      Package Inserts

      Overview

      Transform Specimen Processing for COVID Testing

      No uncapping and no specimen transfer. Expedite your SARS-CoV-2* workflow with a collection device that loads directly on the Panther® system. The Direct Load Tube Collection Kit is authorized for use with the Aptima® SARS-CoV-2 and Aptima SARS-CoV-2/Flu assays. 

      Deliver Results Sooner

      Load directly into the Panther System.

      • Directly load alongside specimen types for other assays with true random and continuous access.
      • Non-hazardous lysis buffer reduces risk by inactivating common respiratory viruses, minimizing biosafety needs.
      • Penetrable cap eliminates uncapping and recapping of tube.

      Traditional 8-Step Respiratory Specimen Workflow

      1

      Uncap Collection Tube

       

      2

      Uncap Transfer Tube

       

      3

      Transfer Primary Specimen

       

      4

      Recap Transfer Tube

       

      5

      Recap Collection Tube

       

      6

      Mix Transfer Tube

       

      7

      Uncap Transfer Tube

       

      8

      Load Onto System

       

      Reduce Labor/Costs/Risk with Fewer Steps

      • Eliminate manual uncapping and recapping.
      • One collection kit for nasal and OP swabs.
      • Remove manual specimen transfer steps.
      • Inactivates common respiratory viruses.
      • Reduce human error and repetitive motion injuries.
      • Guanidine free, non-toxic media.
      • Reduce costs for additional consumables.       
      • Penetrable cap serves as additional cross-contamination barrier.
      * The Aptima SARS-CoV-2 and Aptima SARS-CoV-2/Flu assays have not been FDA cleared or approved; These tests have been authorized by FDA under an EUA for use by authorized laboratories; The Aptima SARS-CoV-2 assay has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens; The Aptima SARS-CoV-2/Flu assay  has been authorized only for the simultaneous qualitative detection and differentiation of nucleic acid from SARS-CoV-2, Flu A and Flu B and not for any other viruses or pathogens. The Aptima SARS-CoV-2 and Aptima SARS-CoV-2/Flu assays are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. 
      Package Inserts

      Find Support

      All Other Requests

      Related Products

      International Content